Discoid lupus erythematosus

New Research on Emerging Cutaneous Lupus Erythematosus (CLE) Market Reveals Vast Potential for Pipeline Agents, According to Spherix Global Insights

Retrieved on: 
Monday, May 8, 2023

EXTON, Pa., May 8, 2023 /PRNewswire/ -- According to the Lupus Foundation of America, approximately two-thirds of people with the autoimmune condition systemic lupus erythematosus (SLE) will develop some type of skin disease, called cutaneous lupus erythematosus (CLE). Skin disease in lupus can cause rashes or lesions, most of which will appear on the sun-exposed areas of the body.

Key Points: 
  • EXTON, Pa., May 8, 2023 /PRNewswire/ -- According to the Lupus Foundation of America , approximately two-thirds of people with the autoimmune condition systemic lupus erythematosus (SLE) will develop some type of skin disease, called cutaneous lupus erythematosus (CLE).
  • Skin disease in lupus can cause rashes or lesions, most of which will appear on the sun-exposed areas of the body.
  • – Rheumatologist
    There are currently no specific FDA-approved therapies for cutaneous lupus erythematosus (CLE) or discoid lupus erythematosus (DLE) – conditions which mostly affect women and people of color.
  • Spherix Global Insight's Market Dynamix™ Cutaneous Lupus Erythematosus service focuses on this evolving market, where a paradigm shift is expected within the next few years.

Lupus Research Alliance Grants 2023 Lupus Innovation Awards to Advance Ground-Breaking Lupus Research

Retrieved on: 
Thursday, March 23, 2023

NEW YORK, March 23, 2023 /PRNewswire/ --The Lupus Research Alliance (LRA) today announced the recipients of the newest Lupus Innovation Award (LIA) grants.

Key Points: 
  • NEW YORK, March 23, 2023 /PRNewswire/ --The Lupus Research Alliance (LRA) today announced the recipients of the newest Lupus Innovation Award (LIA) grants.
  • "We are proud to be able to offer these grants, which support critical lupus research and encourage the development of novel therapeutic approaches.
  • The LRA LIA grants provide support for pioneering, high-risk, high-reward approaches to significant challenges in lupus research.
  • This research will increase the understanding of how lupus impacts the brain and help identify new potential treatment targets for neuropsychiatric lupus.

Lupus Foundation of America Awards Four Grants Supporting Early Career Scientists, Funding Critical Areas of Research

Retrieved on: 
Thursday, December 1, 2022

This year's grantees will focus their research on pediatric lupus, neuropsychiatric lupus and cognitive challenges, and potential new treatment pathways.

Key Points: 
  • This year's grantees will focus their research on pediatric lupus, neuropsychiatric lupus and cognitive challenges, and potential new treatment pathways.
  • Each research study by the CDA grantees will strategically advance the Foundation's research agenda, which includes serving as the leader in supporting childhood lupus research.
  • Lupus is debilitating and destructive and can be fatal, yet research on lupus remains underfunded relative to diseases of similar scope and devastation.
  • Through a comprehensive program of research, education, and advocacy, we lead the fight to improve the quality of life for all people affected by lupus.

The Journal Lupus Publishes Investigator-Initiated Study Results Demonstrating Improved Executive Function in Patients with Systemic Lupus Erythematosus Following Use of Akili’s AKL-T01 Product Candidate

Retrieved on: 
Thursday, July 14, 2022

Data from the study show that AKL-T01 resulted in significant improvement in motor speed and executive functions.

Key Points: 
  • Data from the study show that AKL-T01 resulted in significant improvement in motor speed and executive functions.
  • Further, the study investigated the ability of the product EVOTM Monitor5, built on the same technology platform, to serve as a rapid mobile assessment of cognitive function.
  • The results of this study in patients with SLE are consistent with the cognitive improvements seen in other studies after using our digital therapeutic.
  • Cognitive impairment in systemic lupus erythematosus is negatively related to social role participation and quality of life: a systematic review.

Horizon Therapeutics plc Announces New Development Programs at Virtual R&D Day

Retrieved on: 
Wednesday, September 29, 2021

Horizon Therapeutics plc (Nasdaq: HZNP) will present an overview of its pipeline, including five new development programs for investigational medicines, daxdilimab (HZN-7734) and dazodalibep (HZN-4920), in new disease areas today during its first virtual R&D Day for investors and analysts.

Key Points: 
  • Horizon Therapeutics plc (Nasdaq: HZNP) will present an overview of its pipeline, including five new development programs for investigational medicines, daxdilimab (HZN-7734) and dazodalibep (HZN-4920), in new disease areas today during its first virtual R&D Day for investors and analysts.
  • The virtual event will be held from 9 a.m. to approximately 12:30 p.m. Eastern Time and may be accessed at https://horizonrdinvestorday.stagepro.io/ .
  • Todays announcement of new development programs, new disease areas and increased investment in our drug discovery activity further diversifies our portfolio and positions us for long-term growth.
  • With the addition of five new development programs, Horizon now has 27 development programs across its pipeline.